Liu M - Search Results

1

Prioritizing vaccine introduction to China's National Immunization Program: a multi-criteria decision analysis.

Guo J, Zheng B, Chen T, Guo S, Liu M, Dong S. Guo J, et al. Among authors: liu m. BMC Public Health. 2024 Dec 18;24(1):3458. doi: 10.1186/s12889-024-21013-7. BMC Public Health. 2024. PMID: 39695502 Free PMC article.

2

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, Zhan FM, Liu MB. Li N, et al. Clin Drug Investig. 2018 Jan;38(1):79-86. doi: 10.1007/s40261-017-0587-z. Clin Drug Investig. 2018. PMID: 29027641

3

From population to individuals: a new indicator for evaluating the appropriateness of clinical application of antibiotics.

Zheng B, Li N, Hu Z, Liu M. Zheng B, et al. Among authors: liu m. BMC Pharmacol Toxicol. 2018 Sep 5;19(1):55. doi: 10.1186/s40360-018-0245-y. BMC Pharmacol Toxicol. 2018. PMID: 30185217 Free PMC article.

4

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.

Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, Weng L, Liu MB. Cai H, et al. Clin Ther. 2019 Feb;41(2):280-290. doi: 10.1016/j.clinthera.2018.12.007. Epub 2019 Jan 11. Clin Ther. 2019. PMID: 30639208

5

Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.

Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J. Li N, et al. Among authors: liu m. Menopause. 2019 Aug;26(8):906-914. doi: 10.1097/GME.0000000000001339. Menopause. 2019. PMID: 30994577

6

Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial.

Yang J, Weng L, Chen Z, Cai H, Lin X, Hu Z, Li N, Lin B, Zheng B, Zhuang Q, Du B, Zheng Z, Liu M. Yang J, et al. Among authors: liu m. JMIR Mhealth Uhealth. 2019 May 29;7(5):e12542. doi: 10.2196/12542. JMIR Mhealth Uhealth. 2019. PMID: 31144672 Free PMC article. Clinical Trial.

7

Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.

Cai H, Zhang L, Li N, Zheng B, Liu M. Cai H, et al. Among authors: liu m. Leuk Lymphoma. 2019 Dec;60(12):2951-2959. doi: 10.1080/10428194.2019.1620947. Epub 2019 Jun 4. Leuk Lymphoma. 2019. PMID: 31161831

8

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer.

Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Liu M, et al. Cancer Manag Res. 2019 Oct 25;11:9195-9202. doi: 10.2147/CMAR.S223441. eCollection 2019. Cancer Manag Res. 2019. PMID: 31749634 Free PMC article.

9

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.

Liu M, Han S, Zheng B, Cai H, Yang J, Zhuang Q, Li N. Liu M, et al. Cancer Manag Res. 2019 Nov 11;11:9483-9493. doi: 10.2147/CMAR.S226243. eCollection 2019. Cancer Manag Res. 2019. PMID: 31814756 Free PMC article.

10

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Cai H, Zhang L, Li N, Zheng B, Liu M. Cai H, et al. Among authors: liu m. J Comp Eff Res. 2020 Jun;9(8):553-562. doi: 10.2217/cer-2020-0041. Epub 2020 May 18. J Comp Eff Res. 2020. PMID: 32419473 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46,235 results

Search Page

Filters